購物車
幫助
021-54845833/15800441009
|
Background: |
EID3 is highly expressed in testis and shows homology to a region of EID1 implicated in binding to CBP/p300. EID3 acts as a potent inhibitor of nuclear receptor transcriptional activity by a mechanism that is independent of direct interactions with nuclear receptors, including SHP. Furthermore, EID3 directly binds to and blocks the SRC-1 interacting domain of CBP, which has been implicated to act as the interaction surface for nuclear receptor co-activators. Consistent with this idea, EID3 prevents recruitment of CBP to a natural nuclear receptor-regulated promoter. |
|
Applications: |
ELISA, IHC |
|
Name of antibody: |
EID3 |
|
Immunogen: |
Synthetic peptide of human EID3 |
|
Full name: |
EP300 interacting inhibitor of differentiation 3 |
|
Synonyms: |
NS4EB; NSE4B; NSMCE4B |
|
SwissProt: |
Q8N140 |
|
IHC positive control: |
Human gastric cancer and human thyroid cancer |
|
IHC Recommend dilution: |
25-100 |
